Quick Answer
Camp4 Therapeutics Corp reported Total Revenue of $3.50 million for fiscal year 2025.
Camp4 Therapeutics Corp — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Revenue | $3.50M +436.5% |
$652.0K +86.3% |
$350.0K | — |
| Net Income | -$80.40M -55.2% |
-$51.79M -5.1% |
-$49.29M | — |
| Diluted EPS | -$2.65 +76.0% |
-$11.04 +91.2% |
-$124.80 | — |
| Total Assets | $117.81M +50.4% |
$78.31M +42.5% |
$54.95M | — |
| Cash and Equivalents | $109.52M +71.0% |
$64.04M +66.9% |
$38.38M | — |
| Stockholders Equity | $47.70M -24.5% |
$63.14M +151.0% |
-$123.73M -59.6% |
-$77.53M |
| R&D Expense | $38.20M -1.6% |
$38.82M -4.4% |
$40.62M | — |
| Operating Income | -$52.55M +1.0% |
-$53.09M -2.3% |
-$51.88M | — |
| Shares Outstanding | 51.90M +157.6% |
20.15M +4272.7% |
460,704 | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $795.0K | — | -46.9% |
| Revenue (ASC 606) | September 30, 2025 | $795.0K | — | -46.9% |
| Net Income | September 30, 2025 | -$15.10M | -12.0% | -20.0% |
| Diluted EPS | September 30, 2025 | -$0.55 | +97.7% | +11.3% |
| Total Assets | September 30, 2025 | $86.39M | +304.4% | +68.5% |
| Cash and Equivalents | September 30, 2025 | $75.25M | +2876.9% | +92.7% |
| Stockholders Equity | September 30, 2025 | $58.67M | +136.9% | +46.7% |
| R&D Expense | September 30, 2025 | $9.36M | -3.6% | -9.5% |
| Operating Income | September 30, 2025 | -$13.65M | -1.0% | -4.8% |
| Shares Outstanding | September 30, 2025 | 46.88M | +4560.4% | +132.5% |
- Camp4 Therapeutics Corp reported Total Revenue of $3.50 million for fiscal year 2025.
- Camp4 Therapeutics Corp showed an increase of +436.5% in Total Revenue compared to the prior fiscal year.
- Camp4 Therapeutics Corp reported Net Income of -$80.40 million for fiscal year 2025.
- Camp4 Therapeutics Corp showed a decrease of -55.2% in Net Income compared to the prior fiscal year.
- Camp4 Therapeutics Corp reported Diluted EPS of $2.65 per share (loss) for fiscal year 2025.
- Camp4 Therapeutics Corp showed an increase of +76.0% in Diluted EPS compared to the prior fiscal year.
- Camp4 Therapeutics Corp reported Total Assets of $117.81 million for fiscal year 2025.
- Camp4 Therapeutics Corp showed an increase of +50.4% in Total Assets compared to the prior fiscal year.
- Camp4 Therapeutics Corp reported Cash and Equivalents of $109.52 million for fiscal year 2025.
- Camp4 Therapeutics Corp showed an increase of +71.0% in Cash and Equivalents compared to the prior fiscal year.
- Camp4 Therapeutics Corp reported Stockholders Equity of $47.70 million for fiscal year 2025.
- Camp4 Therapeutics Corp showed a decrease of -24.5% in Stockholders Equity compared to the prior fiscal year.
- Camp4 Therapeutics Corp reported R&D Expense of $38.20 million for fiscal year 2025.
- Camp4 Therapeutics Corp showed a decrease of -1.6% in R&D Expense compared to the prior fiscal year.
- Camp4 Therapeutics Corp reported Operating Income of -$52.55 million for fiscal year 2025.
- Camp4 Therapeutics Corp showed an increase of +1.0% in Operating Income compared to the prior fiscal year.
- Camp4 Therapeutics Corp reported Shares Outstanding of 51.90 million shares for fiscal year 2025.
- Camp4 Therapeutics Corp showed an increase of +157.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: